Titre :

Absence of mortality differences between the 1st and 2nd covid waves in kidney transplant recipients.

Auteur(s) :

Berger, Bastien [Auteur]
Hospices Civils de Lyon [HCL]
Hazzan, Marc [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Kamar, Nassim [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Francois, Hélène [Auteur]
CHU Tenon [AP-HP]
Matignon, Marie [Auteur]
IMRB - I-BIOT/"Immunorégulation et Biothérapie" [Créteil] [U955 Inserm - UPEC]
Greze, Clarisse [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Gatault, Philippe [Auteur]
Université de Tours [UT]
Frimat, Luc [Auteur]
Centre d'investigation clinique - Epidémiologie clinique [Nancy] [CIC-EC]
Westeel, Pierre F. [Auteur]
Goutaudier, Valentin [Auteur]
CHU Montpellier = Montpellier University Hospital
Snanoudj, Renaud [Auteur]
Hôpital Foch [Suresnes]
Colosio, Charlotte [Auteur]
Université de Reims Champagne-Ardenne [URCA]
Sicard, Antoine [Auteur]
Centre Hospitalier Universitaire de Nice [CHU Nice]
Bertrand, Dominique [Auteur]
CHU Rouen
Mousson, Christiane [Auteur]
CHU Dijon
Bamoulid, Jamal [Auteur]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Thierry, Antoine [Auteur]
Université de Poitiers = University of Poitiers [UP]
Anglicheau, Dany [Auteur]
Institut Necker Enfants-Malades [INEM - UM 111 (UMR 8253 / U1151)]
Couzi, Lionel [Auteur]
Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
Chemouny, Jonathan M. [Auteur]
Institut de recherche en santé, environnement et travail [Irset]
École des Hautes Études en Santé Publique [EHESP] [EHESP]
Duveau, Agnes [Auteur]
Université d'Angers [UA]
Moal, Valerie [Auteur]
Assistance Publique - Hôpitaux de Marseille [APHM]
Le Meur, Yannick [Auteur]
Lymphocytes B, Autoimmunité et Immunothérapies [LBAI]
Blancho, Gilles [Auteur]
Nantes Université [Nantes Univ]
Tourret, Jerôme [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Malvezzi, Paolo [Auteur]
Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
Mariat, Christophe [Auteur]
Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] [CHU ST-E]
Rerolle, Jean-Philippe [Auteur]
Université de Limoges [UNILIM]
Bouvier, Nicolas [Auteur]
Université de Caen Normandie [UNICAEN]
Caillard, Sophie [Auteur]
Immuno-Rhumatologie Moléculaire [IRM]
Thaunat, Olivier [Auteur]
Centre International de Recherche en Infectiologie [CIRI]

Titre de la revue :

Kidney International Reports

Nom court de la revue :

Kidney Int Rep

Numéro :

7

Pagination :

2617-2629

Date de publication :

2022-10-04

ISSN :

2468-0249

Mot(s)-clé(s) en anglais :

COVID-19
SARS-CoV-2
transplantation

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Introduction SARS-CoV-2 pandemic evolved in 2 consecutive waves during 2020. Improvements in the management of COVID-19 led to a reduction in mortality rates among hospitalized patients during the second wave. Whether ...
Lire la suite >Introduction SARS-CoV-2 pandemic evolved in 2 consecutive waves during 2020. Improvements in the management of COVID-19 led to a reduction in mortality rates among hospitalized patients during the second wave. Whether this progress benefited kidney transplant recipients (KTRs), a population particularly vulnerable to severe COVID-19, remained unclear. Methods In France, 957 KTRs were hospitalized for COVID-19 in 2020 and their data were prospectively collected into the French Solid Organ Transplant (SOT) COVID registry. The presentation, management, and outcomes of the 359 KTRs diagnosed during the first wave were compared to those of the 598 of the second wave. Results Baseline comorbidities were similar between KTRs of the 2 waves. Maintenance immunosuppression was reduced in most patients but withdrawal of antimetabolite (73.7% vs. 58.4%, P < 0.001) or calcineurin inhibitor (32.1% vs. 16.6%, P < 0.001) was less frequent during the second wave. Hydroxychloroquine and azithromycin that were commonly used during the first wave (21.7% and 30.9%, respectively) but were almost abandoned during the second wave. In contrast, the use of high dose corticosteroids doubled (19.5% vs. 41.6%, P < 0.001). Despite these changing trends in COVID-19 management, 60-day mortality was not statistically different between the 2 waves (25.3% vs. 23.9%; Log Rank, P = 0.48) and COVID-19 hospitalization period was not associated with death due to COVID-19 in multivariate analysis (Hazard ratio 0.89, 95% confidence interval 0.67–1.17, P = 0.4). Conclusion We conclude that changing of therapeutic trends during 2020 did not reduce COVID-19 related mortality among KTRs. Our data indirectly support the importance of vaccination and neutralizing monoclonal anti-SARS-CoV-2 antibodies to protect KTRS from severe COVID-19.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-12T00:31:21Z
2024-03-11T12:47:44Z